EW Weekly, November 2, 2018
- First noninvasive LVC procedures performed
- Clinical program initiated for MK Melt conscious sedation drug
- Phase 3 clinical development program announced for omidenepag isopropyl for glaucoma
- Phase 2 trial results reported for agent used to treat severe dry eye patients
- Zeiss acquires ianTECH
- Companies sign exclusive AI platform agreement for the U.S. market
- FDA approves new bimatoprost solution
- ASCRS/ASOA Annual Meeting Early Bird pricing ends next week
First noninvasive LVC procedures performed
Clinical program initiated for MK Melt conscious sedation drug
Phase 3 clinical development program announced for omidenepag isopropyl for glaucoma
Phase 2 trial results reported for agent used to treat severe dry eye patients
Companies sign exclusive AI platform agreement for the U.S. market
FDA approves new bimatoprost solution
ASCRS/ASOA Annual Meeting Early Bird pricing ends next week
*Must have current membership to attend the Annual Meeting
**Does not include Skills Transfer Labs
Research Briefs
- A new protocol for epithelium-on corneal crosslinking (CXL) stopped the progression of keratoconus and ectasia after LASIK, reported R. Doyle Stulting, MD, and coresearchers. Their prospective observational study used a new riboflavin formulation without epithelial removal then exposed patients to ultraviolet light (365 nm) at 4 mW/cm2 with on/off cycling for 30 minutes. At 3, 6, 12, and 24 months, researchers measured the uncorrected (UDVA) and corrected distance visual acuities (CDVA), total higher-order aberrations, and other parameters. A total of 512 eyes of 308 patients with keratoconus or forme fruste keratoconus and 80 eyes of 55 patients with ectasia after LASIK were treated with the new riboflavin formulation without epithelial removal. A total of 229 patients received bilateral treatments, 95 of which were simultaneous. The mean UDVA and CDVA improved by 1 to 1.5 Snellen lines at 1 and 2 years. Total mean higher-order aberrations and coma lowered by 36% and 37%, respectively. There were no vision-threatening events. The protocol led to a more rapid visual recovery compared with epithelial removal during CXL and allowed for bilateral, simultaneous treatment, the researchers concluded. The study appears in the Journal of Cataract & Refractive Surgery.
- In an elderly, Caucasian population, there was a substantial overdiagnosis of open angle glaucoma (OAG), according to P. Founti and coresearchers. Their cross-sectional, population-based study randomly chose subjects age 60 or older (n=2554) who were part of the Thessaloniki Eye Study in Greece. They defined OAG as the presence of structural and functional damage, irrespective of IOP. An overdiagnosis in non-OAG subjects was defined by a prior glaucoma diagnosis, prior laser for glaucoma, and prior glaucoma surgery. Among the 2.2% subjects with self-reported glaucoma, 60% were overdiagnosed with OAG. Worse visual acuity, a family history of glaucoma, and history of cataract surgery were statistically significantly associated with OAG overdiagnosis. However, age, sex, higher IOP, higher vertical cup-to-disc ratio, and pseudoexfoliation were not significantly associated with overdiagnosis. Glaucoma overdiagnosis has not been previously addressed in population-based studies and needs further examination, the researchers concluded. The study appears in Acta Ophthalmologica.
- Bausch + Lomb (Bridgewater, New Jersey) released its eyeTelligence applications, which will run on the IBM Cloud to help eye surgeons and surgical facilities work more efficiently using the company's Stellaris Elite system.
- Quantel Medical (Cournon D'Auvergne, France) launched its Vitra 810 laser and SubCyclo probe.
- EyeMD EMR Healthcare Systems (Bonita Springs, Florida) debuted its EyeMD EMR 2.0.
This issue of EyeWorld Weekly Update was edited by Amy Goldenberg and Vanessa Caceres.
EyeWorld Weekly Update (ISSN 1089-0319), a digital publication of the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic Administrators, is published every Friday, distributed by email, and posted live on Friday.
Medical Editors: Eric Donnenfeld, MD, chief medical editor; Rosa Braga-Mele, MD, cataract editor; Clara Chan, MD, cornea editor; Nathan Radcliffe, MD, glaucoma editor; and Vance Thompson, MD, refractive editor.
For sponsorship opportunities or membership information, contact:
ASCRS•ASOA • 4000 Legato Rd. • Suite 700 • Fairfax, VA 22033 • Phone: 703-591-2220 • Fax: 703-591-0614 • Email: ASCRS
Opinions expressed in EyeWorld Weekly Update do not necessarily reflect those of ASCRS•ASOA. Mention of products or services does not constitute an endorsement by ASCRS•ASOA.
Click here to view our Legal Notice.